Saurabh Saha Sells 175,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 175,000 shares of the company’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $16.52, for a total transaction of $2,891,000.00. Following the sale, the chief executive officer now directly owns 776,924 shares in the company, valued at $12,834,784.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Saurabh Saha also recently made the following trade(s):

• On Thursday, August 22nd, Saurabh Saha sold 506 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $12.23, for a total value of $6,188.38.
• On Tuesday, August 20th, Saurabh Saha sold 4,169 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $12.32, for a total value of $51,362.08.

Centessa Pharmaceuticals Stock Up 12.5 %

Shares of NASDAQ:CNTA opened at $16.99 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 13.29 and a quick ratio of 13.29. The stock has a market cap of $1.93 billion, a price-to-earnings ratio of -11.96 and a beta of 1.44. The company has a 50 day moving average of $11.76 and a 200-day moving average of $10.49. Centessa Pharmaceuticals plc has a one year low of $5.15 and a one year high of $17.59.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, August 13th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). On average, sell-side analysts forecast that Centessa Pharmaceuticals plc will post -1.61 earnings per share for the current year.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quarry LP acquired a new stake in Centessa Pharmaceuticals in the fourth quarter worth $48,000. Sandia Investment Management LP bought a new stake in shares of Centessa Pharmaceuticals in the 2nd quarter valued at $90,000. Fred Alger Management LLC acquired a new stake in Centessa Pharmaceuticals during the 2nd quarter worth $99,000. EntryPoint Capital LLC acquired a new stake in Centessa Pharmaceuticals during the 1st quarter worth $109,000. Finally, Trexquant Investment LP bought a new position in Centessa Pharmaceuticals during the fourth quarter worth about $114,000. Institutional investors own 82.01% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on CNTA. Guggenheim increased their target price on Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday. Jefferies Financial Group raised their price objective on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday. Oppenheimer reiterated an “outperform” rating and set a $14.00 target price on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. BMO Capital Markets raised their price target on shares of Centessa Pharmaceuticals from $15.00 to $20.00 and gave the company an “outperform” rating in a report on Monday, September 9th. Finally, Morgan Stanley upped their price objective on Centessa Pharmaceuticals from $8.00 to $11.00 and gave the stock an “equal weight” rating in a report on Friday, June 21st. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $17.60.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.